Lenalidomide improves survival in previously treated patients with multiple myeloma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2006年 / 20卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [31] Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
    Heuck, Christoph
    Jethava, Yogesh
    Khan, Rashid Z.
    Miller, Scott
    Mitchell, Alan
    Johann, Donald
    Robbins, Kelly
    Van Laar, Ryan K.
    Ali, Siraj
    Miller, Vincent A.
    Bailey, Clyde
    Sawyer, Jeffery
    Zangari, Maurizio
    van Rhee, Frits
    Davies, Faith E.
    Morgan, Gareth J.
    Barlogie, Bart
    BLOOD, 2014, 124 (21)
  • [32] Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)
    Oster, Gerry
    Berger, Ariel
    Bornheimer, Rebecca
    Binder, Gary
    Nagarwala, Yasir
    BLOOD, 2013, 122 (21)
  • [33] Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Phis Dexamethasone in Previously Treated Patients with Multiple Myeloma: The Spanish Experience
    Alegre, Adrian
    Oriol-Rocafiguera, Albert
    Garcia-Larana, Jose
    Mateos, Maria-Victoria
    Sureda, Anna
    Martinez Chamorro, Carmen
    Teresa Cibeira, Maria
    Knight, Robert
    Rosettani, Barbara
    BLOOD, 2010, 116 (21) : 1255 - 1255
  • [34] Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide (vol 46, pg 350, 2011)
    Micallef, I. N. M.
    Ho, A. D.
    Klein, L. M.
    Marulkar, S.
    Gandhi, P. J.
    Calandra, G.
    McSweeney, P. A.
    BONE MARROW TRANSPLANTATION, 2011, 46 (10) : 1398 - 1398
  • [35] BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
    Rossi, Adriana
    Mark, Tomer
    Jayabalan, David
    Christos, Paul
    Zafar, Faiza
    Pekle, Karen
    Pearse, Roger
    Chen-Kiang, Selina
    Coleman, Morton
    Niesvizky, Ruben
    BLOOD, 2013, 121 (11) : 1982 - 1985
  • [36] Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide
    Rollison, Dana E.
    Komrokji, Rami
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Baz, Rachid
    Nishihori, Taiga
    Olesnyckyj, Marta
    Kenvin, Laurie
    Knight, Robert D.
    Sullivan, Daniel M.
    Alsina, Melissa
    Dalton, William
    Shain, Kenneth H.
    BLOOD, 2014, 124 (21)
  • [37] Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
    Huang, Phoebe A.
    Beedie, Shaunna L.
    Chau, Cindy H.
    Venzon, David J.
    Gere, Sheryl
    Kazandjian, Dickran
    Korde, Neha
    Mailankody, Sham
    Landgren, Ola
    Figg, William D.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [38] Survival of Patients with Multiple Myeloma That Is Refractory to Both Bortezomib and Lenalidomide: A Retrospective Study
    Miyazaki, Kanji
    Suzuki, Kenshi
    BLOOD, 2018, 132
  • [39] Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations
    Caravita, Tommaso
    Offidani, Massimo
    Siniscalchi, Agostina
    Gentili, Silvia
    Caraffa, Patrizia
    Perrotti, Alessio
    de Fabritiis, Paolo
    Leoni, Pietro
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (03) : 276 - 277
  • [40] Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
    Rollison, Dana E.
    Komrokji, Rami
    Lee, Ji-Hyun
    Hampras, Shalaka
    Fulp, William
    Fisher, Kate
    Baz, Rachid
    Nishihori, Taiga
    Xu, Qiang
    Olesnyckyj, Marta
    Kenvin, Laurie
    Knight, Robert
    Sullivan, Daniel
    Alsina, Melissa
    Dalton, William
    Shain, Kenneth H.
    LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 560 - 568
12345